Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:17 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 1,709 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infection (HIV) Clear all
Completed Phase 4 Interventional Results available

Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals

NCT01262846
View directory record Official record
Conditions
HIV Infection
Interventions
Fluzone®
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Nov 3, 2026, 5:17 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Video-based Intervention Study to Prevent HIV/Sexually Transmitted Diseases (STDs) Among STD Clinic Patients

NCT00137670
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Video-based HIV/STD prevention intervention
Device
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
45,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
4
States / cities
Long Beach, California • San Francisco, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Nov 3, 2026, 5:17 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

The OPENS Trial: Offering Women PrEP (Aim 1)

NCT04621760
View directory record Official record
Conditions
Human Immunodeficiency Virus Transmission, Sexually Transmitted Diseases
Interventions
HIV Prevention Decision Support Tool (DST), Standard Counseling
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 4 Interventional Results available

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

NCT01691794
View directory record Official record
Conditions
HIV, Pediatric
Interventions
Atazanavir, Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Phoenix, Arizona • Atlanta, Georgia • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Nov 3, 2026, 5:17 PM EST
Completed No phase listed Observational

Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral Load

NCT00025922
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 2 Interventional

A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine

NCT00001688
View directory record Official record
Conditions
HIV Infection
Interventions
Ritonavir, Nevirapine, Stavudine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

NCT03399903
View directory record Official record
Conditions
HIV-1-infection, Gut Inflammation
Interventions
Pentasa vs Align
Drug
Lead sponsor
AIDS Healthcare Foundation
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Nov 3, 2026, 5:17 PM EST
Terminated Phase 1 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02408861
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Nov 3, 2026, 5:17 PM EST
Active, not recruiting Phase 2 Interventional

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

NCT06891066
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISL, ULO, BIC/FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 3, 2026, 5:17 PM EST
Completed No phase listed Observational

Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

NCT00096746
View directory record Official record
Conditions
HIV Infection
Interventions
LPV/RTV + 2NRTIs
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • Altamonte Springs, Florida • Fort Lauderdale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Nov 3, 2026, 5:17 PM EST
Withdrawn No phase listed Observational

Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men

NCT04142385
View directory record Official record
Conditions
HIV Infection
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Medical Examination, Physical Examination, Proctoscopy with Biopsy, Questionnaire Administration
Other · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Nov 3, 2026, 5:17 PM EST
Not listed Phase 2 Interventional

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

NCT00131560
View directory record Official record
Conditions
HIV Infection
Interventions
VRX496-Modified Autologous T cells
Genetic
Lead sponsor
VIRxSYS Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2023
U.S. locations
5
States / cities
Palo Alto, California • Norwalk, Connecticut • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Nov 3, 2026, 5:17 PM EST
Completed Not applicable Interventional

Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection

NCT00490412
View directory record Official record
Conditions
HIV Infections
Interventions
Vitamin D supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Nov 3, 2026, 5:17 PM EST
Terminated Phase 4 Interventional Results available

Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

NCT01791465
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection, Diabetes Mellitus
Interventions
extended-release exenatide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 3 Interventional

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

NCT00110877
View directory record Official record
Conditions
HIV Infection
Interventions
LPV/rtv, TMC114/rtv
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2015 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 3 Interventional Results available

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

NCT00381303
View directory record Official record
Conditions
HIV, Infectious
Interventions
darunavir, ritonavir
Drug
Lead sponsor
Tibotec, Inc
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Nov 3, 2026, 5:17 PM EST
Completed No phase listed Observational

HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs

NCT00001103
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Menlo Park, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

NCT02315703
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose, gp140 DP High-dose, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 2 Interventional Results available

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

NCT01286740
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Nov 3, 2026, 5:17 PM EST
Completed Not applicable Interventional

The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection

NCT00002290
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 5:17 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Using Heavy Water to Study Cell Dynamics in Parkinson's Disease

NCT00990379
View directory record Official record
Conditions
Parkinson's Disease, HIV Infections
Interventions
Not listed
Lead sponsor
Salena Killion
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Nov 3, 2026, 5:17 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission

NCT01053741
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Radiolabeled autologous seminal fluid, Radiolabeled Normosol-R
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Nov 3, 2026, 5:17 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Combatting HIV Or Other STIs Early (CHOOSE)

NCT07510048
View directory record Official record
Conditions
HIV, STIs, STIs Prevention, HIV Prevention
Interventions
Standard of care and PrEP Choice at Enrollment, Standard of care followed by PrEP Choice at Month 9
Other
Lead sponsor
Westat
Other
Eligibility
13 Years to 24 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
6
States / cities
San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 3, 2026, 5:17 PM EST